

Tobacco Cessation Drug Criteria

Created: February 2016 Revised: October 2018, May 2019, December 2021

Includes:

Nicotine Inhaler Nicotine Nasal Spray

Please Note: Nicotine patches, nicotine gum, nicotine lozenges, bupropion SR 150mg tablets, and varenicline tablets are available on the Advanced Health formulary without a prior authorization for up two quit attempts per year as outlined by the Oregon Health Authority Cigarette Smoking Prevalence (Bundled Measure) and the Prioritized List of Health Services Guideline Note 4: Tobacco Dependence, Including During Pregnancy. See Minimum Quantities Table below. For additional information on the Tobacco Cessation metric see:

http://www.oregon.gov/oha/analytics/CCOData/CigaretteSmokingPrevalenceBundle

GUIDELINE FOR USE:

- Has the patient attended a tobacco cessation course within the past 3 months, or are they
 engaged with behavioral health therapy? (Exception to attendance of tobacco cessation course
 allowed for members that live in areas where no tobacco cessation course is offered, or
 member has a physical or mental health condition that restricts their participation in a tobacco
 cessation course. Documentation from the provider must be provided to support the need for
 an exception.)
 - a. If yes, go to step 2
 - b. If no, deny as Criteria Not Met. Member must attend tobacco cessation course for coverage of Nicotine Inhaler or Nicotine Nasal Spray. Nicotine patches, gum, lozenge, bupropion SR 150mg tablets, and varenicline are available without a prior authorization for up to two quit attempts per year on formulary. Use of behavioral health supports with medication therapy optimizes cessation outcomes.
- 2. Has the patient trialed nicotine patches, nicotine gum, nicotine lozenges, bupropion SR 150mg tablets, and varenicline within the past 12 months or have a contraindication to the above listed therapies?
 - a. If yes, approve for 3 months of therapy based on quantity limits outlined below.
 - b. If no, deny as Criteria not met. Nicotine patches, gum, lozenge, bupropion SR 150mg tablets, and varenicline are available without a prior authorization for up to two quit attempts per year on formulary.



Rationale:

To promote utilization of the most cost-effective medication therapies available for tobacco cessation and to encourage participation in behavioral supports to improve outcomes of tobacco cessation efforts for Advanced Health members.

Minimum Quantities Table for Cessation Benefit from CCO Incentive Measure Specification Sheet for Cigarette Smoking Prevalence:

Health

Appendix 1: Minimum Quantities Table for Cessation Benefit

Medication, quantity, and dosage are based on the Public Health Service -Treating Tobacco Use and Dependence: 2008 Update—Clinical Practice Guidelines, online at www.ahrq.gov/professionals/clinicians-providers/guidelines-recommendations/tobacco/clinicians/update/index.html

Medication	Bupropion SR	Varenicline	Nicotine Gum	Nicotine	Nicotine	Nicotine Nasal	Nicotine Patch
			2mg and 4mg	Lozenge	Inhaler 10 mg	Spray	7mg, 14 mg, 21
							mg, 42 mg
Quantity for one quit attempt.	150 mg, 1 box of 60 tablets = 30 day supply x 3 (90 days) = 3 boxes (180) per quit attempt	0.5 mg: 11 tablets per quit attempt 1 mg: One box contains 56 tablets = 30 day	24 maximum per day x 90 days = 2,160 pieces per quit attempt Number of boxes	20 Maximum per day x 12 weeks = 1,800 lozenges16 cartridge maximum per day x 180 days = 0,880 cartridgesMaximum 40 doses per day (80 sprays). 100 doses per bottle per quit attempt2 mg, 72-1682,880 cartridges bottle will last at bottle will last at	1 patch per day x 90 days = 90 patches per quit attempt		
		supply x 3 (90 days) = 3 boxes (168) per quit attempt	depends on quantity per box: 2 mg (packaged in different amounts), boxes of 100–190 pieces) 4 mg (packaged in different amounts), boxes of 100–190 pieces)	lozenges per box 4 mg, 72-168 lozenges per box	17 boxes (1 box has 168 10-mg cartridges)	least 2.5 days. 36 bottle supply for 90 days per quit attempt	

CCO Incentive Measure Specification Sheet for 2016 Measurement Year DRAFTED October 2015 Page 5 of 9

References:

1. Oregon Health Authority. CCO Incentive Measure Specification Sheet for 2016 Measurement Year: Cigarette Smoking Prevalence (Bundled Measure).

2. Health Evidence Review Commission Prioritized List of Health Services. Guideline Note 4: Tobacco Dependence, Including during pregnancy. October 1, 2021.

Approved by Western Oregon Advanced Health Pharmacy and Therapeutics Committee on 3/29/16 Approved by Advanced Health Pharmacy and Therapeutics Committee on 10/22/18, 5/13/19, 1/7/21